RxDoctor Payments Data

Walter Bantom, MD

Internal Medicine · Philadelphia, PANPI 1194741710

Payments from drug & device makers

$659in general payments, 2019–2025

Across 32 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$163
  • Exact Sciences$82
  • Novo Nordisk$73
  • Boehringer Ingelheim$48
  • AbbVie$47
  • AstraZeneca$46
  • plus $201 from 9 others

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$659 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,013
Medicare patients
23
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$52,871
EliquisApixaban43$51,327
JanuviaSitagliptin Phosphate31$27,047
OzempicSemaglutide19$25,431
EntrestoSacubitril/Valsartan17$18,220
TrulicityDulaglutide14$15,409
Breo ElliptaFluticasone/Vilanterol21$8,874
Gvoke Hypopen 2-PackGlucagon13$8,084
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$6,202
Atorvastatin Calcium282$3,723
Losartan Potassium189$2,506
Amlodipine Besylate356$2,365
Valsartan49$1,967
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,569
Amlodipine-ValsartanAmlodipine Besylate/Valsartan29$1,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$48$59,07275 claims
Novo NordiskOzempic$73$25,43119 claims
NovartisEntresto$33$18,22017 claims
GSKBreo Ellipta$19$8,87421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →